Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBB0979 + Topotecan in Relapsed Small Cell Lung Cancer
NCT07076095Phase 2Not yet recruiting
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons
01
Overview
A Phase 2 trial of IBB0979 in small cell lung cancer (SCLC), sponsored by SUNHO BioPharmaceutical. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
IBB0979
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07076095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076095.